INTENSITY THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
INTENSITY THERAPEUTICS, INC. (INTS) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$2.44 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-27
- INTENSITY THERAPEUTICS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$2.44M.
- INTENSITY THERAPEUTICS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$3.41M.
- INTENSITY THERAPEUTICS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$2.21M.
- INTENSITY THERAPEUTICS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$1.59M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$2.44M 10-K · filed 2026-03-27 |
| 2024-12-31 | -$3.41M 10-K · filed 2026-03-27 |
| 2023-12-31 | -$2.21M 10-K · filed 2025-03-13 |
| 2022-12-31 | -$1.59M 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |